Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Accounts Receivables
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
|
Accounts Receivables
zł12.8m
|
CAGR 3-Years
42%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
M
|
Mabion SA
WSE:MAB
|
Accounts Receivables
zł791k
|
CAGR 3-Years
-79%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-15%
|
|
|
R
|
Read Gene SA
WSE:RDG
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bioton SA
WSE:BIO
|
Accounts Receivables
zł20.7m
|
CAGR 3-Years
62%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
U
|
Urteste SA
WSE:URT
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Synthaverse SA
WSE:SVE
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Glance View
Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 223 full-time employees. The company went IPO on 2011-07-29.
See Also
What is Biomed Lublin Wytwornia Surowic i Szczepionek SA's Accounts Receivables?
Accounts Receivables
12.8m
PLN
Based on the financial report for Dec 31, 2022, Biomed Lublin Wytwornia Surowic i Szczepionek SA's Accounts Receivables amounts to 12.8m PLN.
What is Biomed Lublin Wytwornia Surowic i Szczepionek SA's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
18%
Over the last year, the Accounts Receivables growth was 24%. The average annual Accounts Receivables growth rates for Biomed Lublin Wytwornia Surowic i Szczepionek SA have been 42% over the past three years , 18% over the past five years .
